Abstract 5239: KRAS wild-type status as detected by circulating tumor DNA analysis may be a prognostic or predictive factor for clinical benefit in patients with unresectable, locally advanced or metastatic pancreatic cancer (PC) treated with the MEK inhibitor refametin

MLA

Marius Giurescu, et al. “Abstract 5239: KRAS Wild-Type Status as Detected by Circulating Tumor DNA Analysis May Be a Prognostic or Predictive Factor for Clinical Benefit in Patients with Unresectable, Locally Advanced or Metastatic Pancreatic Cancer (PC) Treated with the MEK Inhibitor Refametin.” Cancer Research, vol. 75, Aug. 2015, p. 5239. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi...........47dc3221d0fb0e7bb10102773faf1ba3&authtype=sso&custid=ns315887.

APA

Marius Giurescu, Jean-Luc Van Laethem, Vittorio Luigi Garosi, Henrik Seidel, Richardus Vonk, Hanno Riess, Anke Schulz, Michael Teufel, Barrett H. Childs, & Joachim Reischl. (2015). Abstract 5239: KRAS wild-type status as detected by circulating tumor DNA analysis may be a prognostic or predictive factor for clinical benefit in patients with unresectable, locally advanced or metastatic pancreatic cancer (PC) treated with the MEK inhibitor refametin. Cancer Research, 75, 5239.

Chicago

Marius Giurescu, Jean-Luc Van Laethem, Vittorio Luigi Garosi, Henrik Seidel, Richardus Vonk, Hanno Riess, Anke Schulz, Michael Teufel, Barrett H. Childs, and Joachim Reischl. 2015. “Abstract 5239: KRAS Wild-Type Status as Detected by Circulating Tumor DNA Analysis May Be a Prognostic or Predictive Factor for Clinical Benefit in Patients with Unresectable, Locally Advanced or Metastatic Pancreatic Cancer (PC) Treated with the MEK Inhibitor Refametin.” Cancer Research 75 (August): 5239. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi...........47dc3221d0fb0e7bb10102773faf1ba3&authtype=sso&custid=ns315887.